follicular B-cell lymphoma; follicular center lymphoma; chronic lymphatic leukemia type 2

From Aaushi
Jump to navigation Jump to search

Epidemiology

Pathology

Microscopic pathology

  • grade I: small cell
  • grade II: mixed small and large cells
  • grade III: large cell

Immunophenotype

Genetics

Clinical manifestations

Laboratory

Diagnostic procedures

Radiology

Complications

Management

More general terms

More specific terms

Additional terms

References

  1. Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 402, 700-704
  2. Cotran et al Robbins Pathologic Basis of Disease, W.B. Saunders Co, Philadelphia, PA 1989 pg 711-713
  3. Chan JK, Banks PM, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Harris NL, Isaacson PG, et al. A revised European-American classification of lymphoid neoplasms proposed by the International Lymphoma Study Group. A summary version. Am J Clin Pathol. 1995 May;103(5):543-60. PMID: https://www.ncbi.nlm.nih.gov/pubmed/7741099
  4. WHO Classification Tumours of Haematopoietic and Lymphoid Tissues. Jaffe et al. eds. IARC Press 2001
  5. 5.0 5.1 Van Oers MHJ et al, Rituximab maintenance improves clinical outcome of relapsed/ resistance follicular non-Hodgkin lymphoma in patients with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 2006, 108:3295 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16873669
  6. 6.00 6.01 6.02 6.03 6.04 6.05 6.06 6.07 6.08 6.09 6.10 6.11 6.12 Medical Knowledge Self Assessment Program (MKSAP) 15, 16, 17, 18, 19. American College of Physicians, Philadelphia 2009, 2012, 2015, 2018, 2021.
  7. Hainsworth JD, Litchy S, Burris HA et al Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol. 2002 Oct 15;20(20):4261-7. PMID: https://www.ncbi.nlm.nih.gov/pubmed/12377971
  8. Czuczman M, Straus D, Gribben J, Bredenfeld H et al Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomas. Leuk Lymphoma. 2010 Aug;51 Suppl 1:41-9 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20658953
  9. Buske C, Hoster E, Dreyling M et al The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006 Sep 1;108(5):1504-8. Epub 2006 May 11. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16690968
  10. 10.0 10.1 10.2 10.3 Link BK et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: A report from the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 2013 Sep 10; 31:3272 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23897955 <Internet> http://jco.ascopubs.org/content/31/26/3272
  11. Li ZM, Ghielmini M, Moccia AA. Managing newly diagnosed follicular lymphoma: state of the art and future perspectives. Expert Rev Anticancer Ther. 2013 Mar;13(3):313-25 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23477518
  12. Hochberg EP, Bierer MF, Winkfield KM et al Case 11-2017 - A 61-Year-Old Woman with Leg Swelling, Back Pain, and Hydronephrosis. N Engl J Med 2017; 376:1461-1471. April 13, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28402765 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMcpc1616023
  13. 13.0 13.1 Ingram I Ditching Chemo Appears Viable in Frontline Follicular Lymphoma. PFS 'nearly identical' at 3 years with novel immunomodulatory combination. MedPage Today. June 06, 2018 https://www.medpagetoday.com/meetingcoverage/asco/73327
    Fowler NH, et al RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma. American Society of Clinical Oncology (ASCO) 2018; Abstract 7500.
  14. Casulo C, Burack WR, Friedberg JW. Transformed follicular non-Hodgkin lymphoma. Blood. 2015 Jan 1;125(1):40-7. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25499449 Free Article
  15. Kahl BS, Yang DT. Follicular lymphoma: evolving therapeutic strategies. Blood. 2016 Apr 28;127(17):2055-63. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26989204 Free Article

Patient information

follicular lymphoma patient information

Database